Health & Fitness
Health and Fitness
Health and Fitness
Tue, August 3, 2010
Mon, August 2, 2010 AVEO Pharmaceuticals to Present at Cancer Stem Cells & The Tumor Microenvironment Conference
CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that Murray Robinson, Ph.D., senior vice president, translational medicine, is scheduled to present at the Cancer Stem Cells & The Tumor Microenvironment Conference, part of IBCa™s Drug Discovery & Development Week, on Monday, August 2, 2010 at 1:45 p.m. (PDT) at the Hyatt Regency San Francisco Airport in San Francisco.
"Myeloid Resistance Biomarkers for the VEGFR TKI Tivozanib Identified Using Next Generation Tumor Models"
Dr. Robinson will give a presentation, entitled aMyeloid Resistance Biomarkers for the VEGFR TKI Tivozanib Identified Using Next Generation Tumor Models,a that will focus on the utility of AVEOa™s specific myeloid based multi-gene and IHC resistance biomarkers in assessing the activity of tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2 and 3, in human renal cell carcinoma (RCC).
About AVEO
AVEO Pharmaceuticals (NASDAQ: AVEO) blends a proprietary cancer biology platform with drug development and commercial expertise to discover and develop targeted cancer therapeutics. The companya™s lead product, tivozanib, is an oral, triple VEGF receptor inhibitor with a highly differentiated profile. Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types. AVEOa™s proprietary, integrated cancer biology platform offers the company a unique advantage in oncology drug development and has provided a discovery engine for high-value targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets includingHGF, ErbB3, RON, Notch andFGFR. For more information, please visit the company's website at [ www.aveopharma.com ].
